How They Convinced Millions to Take This CHOLESTEROL Pill for Life

Berg emphasizes that the conventional lipid panel only reports total LDL cholesterol concentration, which conflates the harmful and harmless forms. Many people on a healthy low-carb diet show elevated LDL but produce exclusively the large buoyant type, yet standard doctors alarm them and may prescribe statins. The advanced test resolves this ambiguity. He also notes that inflammation and tissue repair increase cholesterol demand, so a high LDL could be a response to damage rather than a cause. The particle size test helps differentiate whether the high LDL is a repair response (often large particles) or a sign of metabolic derangement (small dense particles).

Berg draws a direct line from dietary sugar and starches to cholesterol elevation: excess refined carbs are converted into cholesterol and triglycerides, increasing small dense LDL. He argues that cholesterol is not the root cause of cardiovascular disease but a downstream marker of the metabolic environment. By improving insulin sensitivity through diet, patients not only improve their particle size profile but also reduce inflammation and the overall need for cholesterol as a repair molecule. This positions dietary intervention as the true treatment, rather than a statin that merely blocks a downstream enzyme without addressing metabolic dysfunction.

Berg raises this point to illustrate that cholesterol elevation can be a physiological response rather than a disease. He suggests that instead of prescribing a statin, clinicians should investigate whether the patient is under sustained stress. If so, addressing the stress could naturally lower cholesterol without drugs. This dovetails with his broader argument that high cholesterol is often a symptom, not a cause, and should prompt a search for the underlying demand—emotional, inflammatory, or hormonal.

Berg observes that in nature, cholesterol goes up in winter and down in summer, a pattern he attributes to sunlight-driven conversion into vitamin D. He speculates that modern humans, who spend most of their time indoors, are effectively in a permanent winter, causing cholesterol to build up because the normal seasonal outlet is missing. This reframes high cholesterol as potentially a vitamin D insufficiency signal. The solution is to get sun, not to block the cholesterol pathway with drugs. He also notes that low cholesterol itself impairs vitamin D synthesis, creating a vicious cycle.

Berg mentions this briefly, noting he has a dedicated video on the topic. He presents CoQ10 depletion as one of the two key reasons (along with testosterone suppression) why statins cause muscle problems. The implication is that the standard of care often overlooks this well-documented biochemical effect, leaving patients with debilitating side effects that could be mitigated by simple supplementation—or by reconsidering the drug altogether if the cholesterol elevation is benign.

Berg points out that the body makes 3,000 mg of cholesterol every day regardless of dietary intake; if you eat less, the body makes more. Babies are born with high cholesterol, and the brain is packed with it. He argues that it makes no evolutionary sense for humans to have retained a process that produces a dangerous substance used in cell membranes, steroid hormones, vitamin D activation, bile salts, and tissue repair. The standard blood test measures cholesterol in circulation, but most cholesterol is deep inside cells doing essential structural and signaling work. He critiques the framework where cholesterol is treated like a poison, emphasizing that it’s a building block, not a disease-causing agent. This shift in perspective means that high cholesterol should prompt a search for why the body is upregulating production (stress, repair, inflammation, insulin resistance) rather than an automatic attempt to crush it with drugs.

Berg describes LDL as cargo trucks carrying cholesterol: HDL brings cholesterol back to the liver for recycling, while LDL delivers cholesterol to cells. Within LDL, two particle sizes exist. Small dense LDL forms when glucose is high and insulin resistance is present—typically in a high-carbohydrate, inflammatory environment—and these small particles can invade the arterial lining and provoke inflammation. In contrast, large buoyant LDL particles are too big to infiltrate the vessel wall and are not pathogenic. He stresses that individuals on a low-carb diet with good insulin sensitivity will predominantly produce large buoyant LDL, so a high LDL reading in that context may be harmless. The key is to obtain an advanced lipid profile test that measures particle size and number, rather than relying on the basic panel that lumps all LDL together. Without that distinction, healthy people can be frightened into taking statins for a non-issue.

Berg states that low cholesterol is associated with higher rates of death from all causes in older adults, contradicting the assumption that lower is always safer. He explains that cholesterol is essential for brain structure (the brain is mostly fat) and for synthesizing hormones like testosterone and cortisol, as well as vitamin D and bile acids. When cholesterol is too low, individuals may suffer from depression, memory problems, reduced immune function, and hormone deficiencies. He points out the asymmetry: doctors will prescribe statins for high cholesterol but never say “your cholesterol is too low, we need to raise it.” This institutional silence means that patients whose cholesterol is driven very low by medication may be experiencing harm without any clinical recognition. Berg argues that the risk-benefit calculus of cholesterol lowering must account for these underappreciated consequences.

Berg explains that cholesterol is the raw material for all steroid hormones, including testosterone and the stress hormone cortisol. When a statin blocks the enzyme HMG-CoA reductase to shut down cholesterol synthesis, it also cuts off the supply for these downstream hormones. The result is reduced testosterone production, which particularly affects muscle health because testosterone plays a key role in muscle maintenance and repair. Additionally, the same metabolic pathway produces coenzyme Q10 (ubiquinone), a molecule critical for mitochondrial energy production in muscles; statins simultaneously block CoQ10 synthesis. This dual hit—lower testosterone and depleted CoQ10—explains why statin users often complain of muscle pain, weakness, and reduced stamina. He references a separate video where he covers the CoQ10 issue in more depth, but the takeaway is that the drug’s benefits must be weighed against these predictable biochemical disruptions.